{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:53Z","timestamp":1792425353427,"version":"4.5.0"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224963","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T13:28:20Z","timestamp":1575293300000},"page":"e0224963","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":31,"title":["A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4316-0771","authenticated-orcid":true,"given":"Nat\u00e1lia Sarzi","family":"Sartori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Picon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afonso","family":"Papke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeruza Lavanholi","family":"Neyeloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Mendon\u00e7a","family":"da Silva Chakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"issue":"5","key":"pone.0224963.ref001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00408-013-9481-5","article-title":"Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea","volume":"191","author":"SK Lee","year":"2013","journal-title":"Lung"},{"issue":"4","key":"pone.0224963.ref002","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10096-008-0628-x","article-title":"Risk factors for opportunistic infections in infliximab-treated patients: The importance of screening in prevention","volume":"28","author":"C Garcia-Vidal","year":"2009","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"pone.0224963.ref003","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","volume":"48","author":"JJ G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"4","key":"pone.0224963.ref004","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/s10165-011-0541-5","article-title":"Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients","volume":"22","author":"T Koike","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0224963.ref005","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/rheumatology\/keq368","article-title":"Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries","volume":"50","author":"X Mariette","year":"2011","journal-title":"Rheumatology"},{"issue":"2","key":"pone.0224963.ref006","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: Infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"GR Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"no. 3","key":"pone.0224963.ref007","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/03009742.2016.1202318","article-title":"A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study,","volume":"vol. 46","author":"Y. M. Chiu","year":"2017","journal-title":"Scand. J. Rheumatol."},{"issue":"7","key":"pone.0224963.ref008","first-page":"1170","article-title":"Occurrence of adverse events in patients with JIA receiving biologic agents: Long-term follow-up in a real-life setting","volume":"54","author":"M Tarkiainen","year":"2015","journal-title":"Rheumatol (United Kingdom)"},{"issue":"2","key":"pone.0224963.ref009","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/1756-185X.12970","article-title":"Comparison of the risk of infections in different anti-TNF agents: a meta-analysis","volume":"20","author":"H Liao","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"pone.0224963.ref010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"T Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0224963.ref011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/35095558","article-title":"How can immunology contribute to the control of tuberculosis?","volume":"1","author":"SH Kaufmann","year":"2001","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pone.0224963.ref012","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrmicro1538","article-title":"Who puts the tubercle in tuberculosis?","volume":"5","author":"DG Russell","year":"2007","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"pone.0224963.ref013","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"RS Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0224963.ref014","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.autrev.2008.11.002","article-title":"Serious infections during anti-TNF?? treatment in rheumatoid arthritis patients","volume":"8","author":"EG Favalli","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"12","key":"pone.0224963.ref015","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-alpha Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry\/Cohort Studies","volume":"42","author":"JW Ai","year":"2015","journal-title":"J Rheumatol"},{"key":"pone.0224963.ref016","unstructured":"WHO. Global Tuberculosis Report 2017. World Health Organization. 2017. 1\u2013262 p."},{"issue":"61","key":"pone.0224963.ref017","author":"Minist\u00e9rio da Sa\u00fade. Secretaria de Vigilancia em Sa\u00fade. Departamento de Vigilancia Epidemiologica","year":"2011","journal-title":"Manual de Recomenda\u00e7\u00f5es para o Controle da Tuberculose no Brasil"},{"issue":"11","key":"pone.0224963.ref018","first-page":"18","article-title":"Implanta\u00e7\u00e3o do Plano Nacional pelo Fim da Tuberculose como Problema de Sa\u00fade P\u00fablica no Brasil: primeiros passos rumo ao alcance das metas","volume":"49","author":"BRASIL M da SS de V em S","year":"2018","journal-title":"Bol Epidemiol\u00f3gico 11"},{"issue":"10","key":"pone.0224963.ref019","article-title":"Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis","volume":"9","author":"JJ Yeh","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"pone.0224963.ref020","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"J Askling","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"12","key":"pone.0224963.ref021","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.5588\/ijtld.13.0368","article-title":"Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan","volume":"17","author":"W-M Ke","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"pone.0224963.ref022","first-page":"1","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","author":"EV Arkema","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"pone.0224963.ref023","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"X Wang","year":"2019","journal-title":"Rheumatology"},{"issue":"4","key":"pone.0224963.ref024","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/crj.12726","article-title":"Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk","volume":"12","author":"T Cagatay","year":"2018","journal-title":"Clin Respir J"},{"issue":"4","key":"pone.0224963.ref025","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with Rheumatoid Arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"S-S Seong","year":"2007","journal-title":"J Rheumatol"},{"issue":"10","key":"pone.0224963.ref026","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1590\/S1806-37132009001000011","article-title":"III Diretrizes para Tuberculose da Sociedade Brasileira de Pneumologia e Tisiologia","volume":"35","author":"MB Conde","year":"2009","journal-title":"J Bras Pneumol"},{"issue":"2","key":"pone.0224963.ref027","first-page":"152","article-title":"Reumatologia para o tratamento da artrite reumatoide","volume":"52","author":"L Maria","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"6","key":"pone.0224963.ref028","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"F Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"pone.0224963.ref029","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"JJ Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"12","key":"pone.0224963.ref030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.medcli.2010.11.032","article-title":"Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry","volume":"137","author":"MJ P\u00e9rez-Sola","year":"2011","journal-title":"Med Clin (Barc)"},{"issue":"S 2","key":"pone.0224963.ref031","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","article-title":"Incid\u00eancia de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas BiobadaBrasil","volume":"57","author":"CL Yonekura","year":"2017","journal-title":"Rev Bras Reumatol"},{"issue":"9","key":"pone.0224963.ref032","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/art.22808","article-title":"Serious infection following anti\u2013tumor necrosis factor \u03b1 therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies","volume":"56","author":"WG Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"pone.0224963.ref033","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","article-title":"Tumor Necrosis Factor Antagonists: Different Kinetics and\/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection","volume":"36","author":"DE Furst","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"pone.0224963.ref034","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic Drugs and the Risk of Tuberculosis","volume":"43","author":"P Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0224963.ref035","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"L Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"pone.0224963.ref036","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents)","volume":"24","author":"JW Baddley","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"pone.0224963.ref037","first-page":"202","volume":"78","author":"RC Siqueira","year":"2019","journal-title":"The potential of the IGRA (Interferon Gamma Release Assay) test for the diagnosis of ocular"},{"issue":"8","key":"pone.0224963.ref038","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5588\/ijtld.13.0755","article-title":"LTBI screening in rheumatoid arthritis patients prior to anti-TNF treatment in an endemic area","volume":"18","author":"KR Bonfiglioli","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"pone.0224963.ref039","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s10067-017-3714-6","article-title":"Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents","volume":"36","author":"G Garziera","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"2","key":"pone.0224963.ref040","article-title":"Resposta atenuada ao PPD no diagn\u00f3stico de infec\u00e7\u00e3o tuberculosa latente em pacientes com artrite reumatoide","volume":"49","author":"CDL Marques","year":"2009","journal-title":"Rev Bras Reumatol"},{"issue":"SUPPL. 2","key":"pone.0224963.ref041","first-page":"37","article-title":"Role of tumour necrosis factor (TNF) in host defence against tuberculosis: Implications for immunotherapies targeting TNF","volume":"62","author":"S Ehlers","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"pone.0224963.ref042","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"MA Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"pone.0224963.ref043","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists","volume":"38","author":"RS Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0224963.ref044","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","article-title":"Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis","volume":"29","author":"M Lahiri","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"pone.0224963.ref045","first-page":"145","article-title":"Registro Brasileiro de Biol\u00f3gicos\u202f: preliminares do BiobadaBrasil","volume":"51","author":"DC Titton","year":"2011","journal-title":"Rev Bras Reum"},{"issue":"3","key":"pone.0224963.ref046","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.150177","article-title":"Characteristics predicting tuberculosis risk under tumor necrosis factor-\u03b1 inhibitors: Report from a large multicenter cohort with high background prevalence","volume":"43","author":"B Kisacik","year":"2016","journal-title":"J Rheumatol"},{"issue":"12","key":"pone.0224963.ref047","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s10067-015-3099-3","article-title":"Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom","volume":"34","author":"MK Nisar","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"6","key":"pone.0224963.ref048","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keh567","article-title":"TNF-blocking agents and tuberculosis: New drugs illuminate an old topic","volume":"44","author":"J Keane","year":"2005","journal-title":"Rheumatology"},{"issue":"10","key":"pone.0224963.ref049","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"L Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"pone.0224963.ref050","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00296-011-2017-5","article-title":"Tuberculosis infection in rheumatic patients with infliximab therapy: Experience with 157 patients","volume":"32","author":"CA Nobre","year":"2012","journal-title":"Rheumatol Int"},{"issue":"3","key":"pone.0224963.ref051","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"WG Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"pone.0224963.ref052","first-page":"183","author":"B Denis","year":"2007","journal-title":"Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-a antagonist therapy: safe re-initiation of TNF-a blockers after appropriate anti-tuberculous treatment"},{"key":"pone.0224963.ref053","first-page":"33","article-title":"Factors Associated with Mortality in Hospitalized Patients with Newly Diagnosed Tuberculosis","author":"D. Rossato","year":"2010"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T13:28:47Z","timestamp":1575293327000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224963"}},"subtitle":[],"editor":[{"given":"Mahmoud","family":"Abu-Shakra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224963","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]}}}